Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05424822




Registration number
NCT05424822
Ethics application status
Date submitted
15/06/2022
Date registered
21/06/2022
Date last updated
23/05/2024

Titles & IDs
Public title
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Scientific title
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants With NHL and CLL
Secondary ID [1] 0 0
2022-000685-18
Secondary ID [2] 0 0
CR109174
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lymphoma, Non-Hodgkin 0 0
Leukemia, Lymphocytic, Chronic, B-Cell 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - JNJ-80948543

Experimental: Part A: Dose Escalation - Participants will receive JNJ-80948543 by subcutaneous (SC) administration to determine the putative recommended Phase 2 dose (RP2D) and dosing schedule(s) based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens.

Experimental: Part B: Cohort Expansion - Participants will receive JNJ-80948543 by SC administration.


Treatment: Drugs: JNJ-80948543
JNJ-80948543 will be administered as SC injection.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants with Dose-limiting Toxicity (DLT)
Timepoint [1] 0 0
Up to 2 Years 5 months
Primary outcome [2] 0 0
Number of Participants with Adverse Events (AEs)
Timepoint [2] 0 0
Up to 2 Years 5 months
Primary outcome [3] 0 0
Number of Participants with AE by Severity
Timepoint [3] 0 0
Up to 2 Years 5 months
Secondary outcome [1] 0 0
Serum Concentration of JNJ-80948543
Timepoint [1] 0 0
Up to 2 Years 5 months
Secondary outcome [2] 0 0
Number of Participants with Presence of Anti-Drug Antibodies of JNJ-80948543
Timepoint [2] 0 0
Up to 2 Years 5 months
Secondary outcome [3] 0 0
Overall Response Rate (ORR)
Timepoint [3] 0 0
Up to 2 Years 5 months
Secondary outcome [4] 0 0
Complete Response (CR) Rate
Timepoint [4] 0 0
Up to 2 Years 5 months
Secondary outcome [5] 0 0
Rate of VGPR or Better for Participants with Waldenstrom Macroglobulinemia (WM)
Timepoint [5] 0 0
Up to 2 Years 5 months
Secondary outcome [6] 0 0
Time to Response (TTR)
Timepoint [6] 0 0
Up to 2 Years 5 months
Secondary outcome [7] 0 0
Duration of Response (DOR)
Timepoint [7] 0 0
Up to 2 Years 5 months

Eligibility
Key inclusion criteria
- Histologic documentation of disease: B-cell non-Hodgkin lymphoma (NHL) or chronic
lymphocytic leukemia (CLL) requiring therapy.

All participants must have relapsed or refractory disease with no other approved therapies
available that would be more appropriate in the investigator's judgment.

B-cell NHL as defined per the 2016 world health organization (WHO) classification. In
addition, the following disease-specific criteria outlined below must be met If diffuse
large B-cell lymphoma (DLBCL) or other high-Grade B-cell lymphoma: Received, or not
eligible for high-dose chemotherapy and autologous stem cell transplantation with curative
intent or deemed not eligible or fit for an alternative 2nd line therapy. Participants may
be eligible if relapsing after chimeric antigen receptors (CAR-T) cell treatment or while
waiting for a CAR-T cell treatment.

If transformed lymphoma from low Grade B-cell malignancies: Received or not a candidate for
an approved first-line regimen for DLBCL and received or not eligible for high-dose
chemotherapy and autologous stem cell transplantation with curative intent.

If follicular lymphoma (FL) (all grades): Previously treated with a minimum of 2 prior
lines of systemic therapy, with at least one prior line containing an anti-CD20 antibody.

If mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) (including nodal,
extranodal/MALT, and splenic MZL subtypes): Previously treated with at least 2 lines of
systemic therapy. H.pylori-positive gastric MALT lymphoma must have failed prior H. pylori
eradication therapy as one of their prior lines .

Waldenstrom macroglobulinemia (WM): Previously treated with at least 1 line of systemic
therapy.

small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL): Relapsed or refractory
with at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTK)
inhibitor or a BCL2 inhibitor, if eligible. In addition for part B Participants must have
measurable disease as defined by the appropriate disease response criteria

- Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1

- Cardiac parameters within the following range: corrected QT interval (QTc intervals
corrected using Fridericia's formula [QTcF]) less than or equal to (<=) 480
milliseconds based on the average of triplicate assessments performed no more than 5
(plus minus [+-] 3) minutes apart

- A female participant of childbearing potential must have a negative highly sensitive
serum pregnancy test (beta- human chorionic gonadotropin) at screening and must agree
to further serum or urine pregnancy tests prior to the first dose, during the study
and until 3 months after the last dose of study treatment

- A female participant must agree not to be pregnant, breastfeeding, or planning to
become pregnant while enrolled in this study or within 3 months after the last dose of
study intervention
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known active central nervous system (CNS) involvement; Lymphoma with CNS involvement
may be allowed in pharmacokinetic/ pharmacodynamic (PK/PD) and expansion cohorts if
approved by the study evaluation team (SET)

- Prior solid-organ transplantation

- Autoimmune or inflammatory disease requiring systemic steroids or other
immunosuppressive agents (example, methotrexate or tacrolimus) within 1 year prior to
first dose of study drug

- Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade
<= 1 (except alopecia, vitiligo, peripheral neuropathy, or endocrinopathies that are
stable on hormone replacement, which may be Grade 2)

- Clinically significant pulmonary compromise, particularly the need for supplemental
oxygen use to maintain adequate oxygenation

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/08/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/10/2026
Actual
Sample size
Target
180
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Macquarie University Hospital - Macquarie University
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [3] 0 0
Linear Clinical Research Ltd - Nedlands
Recruitment hospital [4] 0 0
Scientia Clinical Research - Randwick
Recruitment postcode(s) [1] 0 0
2109 - Macquarie University
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
6009 - Nedlands
Recruitment postcode(s) [4] 0 0
2031 - Randwick
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
New York
Country [3] 0 0
United States of America
State/province [3] 0 0
Tennessee
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
United States of America
State/province [5] 0 0
Washington
Country [6] 0 0
China
State/province [6] 0 0
Guangzhou
Country [7] 0 0
China
State/province [7] 0 0
Tianjin
Country [8] 0 0
China
State/province [8] 0 0
Wuhan
Country [9] 0 0
Denmark
State/province [9] 0 0
Copenhagen
Country [10] 0 0
Denmark
State/province [10] 0 0
Odense
Country [11] 0 0
France
State/province [11] 0 0
Lille Cedex
Country [12] 0 0
France
State/province [12] 0 0
Paris
Country [13] 0 0
France
State/province [13] 0 0
Toulouse Cedex 9
Country [14] 0 0
Israel
State/province [14] 0 0
Haifa
Country [15] 0 0
Israel
State/province [15] 0 0
Jerusalem
Country [16] 0 0
Israel
State/province [16] 0 0
Tel Aviv
Country [17] 0 0
Poland
State/province [17] 0 0
Gdansk
Country [18] 0 0
Poland
State/province [18] 0 0
Skorzewo

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to characterize safety and to determine the putative recommended
Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-80948543 in Part A (Dose
Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in
Part B (Cohort Expansion).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05424822
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Fax 0 0
Email 0 0
Participate-In-This-Study@its.jnj.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05424822